文献速递肝病消化道肿瘤与早癌

不确定性(LI-RADS 3)肝脏观察对象的肝细胞癌风险

Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-12-10

本文综述了肝硬化患者中LI-RADS 3(不确定性)肝脏观察对象的肝细胞癌风险。美国肝病研究学会推荐肝硬化患者每半年行超声和甲胎蛋白筛查,异常者应行多期CT或MRI诊断。LI-RADS将观察对象从LR-1(肯定良性)到LR-5(肯定HCC)分级,LR-3为中等恶性概率。一项999例肝硬化患者研究中,256例超声异常者中98例(38.3%)在诊断性CT或MRI上报告不确定性观察对象。既往研究报告LR-3观察对象的HCC风险范围宽泛,从4%到31%,因此证据不足以推荐标准化监测策略。

要点

  • 美国肝病研究学会推荐肝硬化患者每半年行超声和甲胎蛋白筛查,异常者行多期CT或MRI诊断。
  • LI-RADS将肝脏观察对象从LR-1(肯定良性)到LR-5(肯定HCC)分级,LR-3为中等恶性概率。
  • 既往研究报告LR-3观察对象的HCC风险为4%至31%,证据不足以推荐标准化监测策略。

核心结论

  • 既往研究报告LR-3观察对象的HCC风险范围为4%至31%,证据不足以推荐标准化监测策略。

研究设计与样本

  • 本文为综述,引用一项999例肝硬化患者研究及既往关于LR-3观察对象HCC风险的研究。

主要发现

  • 一项999例肝硬化患者研究中,256例超声异常者中98例(38.3%)在诊断性CT或MRI上报告不确定性肝脏观察对象。
  • 既往研究报告LR-3观察对象的HCC风险范围为4%至31%。

关键数值与推荐

  • 美国肝病研究学会推荐肝硬化患者每半年行超声和甲胎蛋白筛查,异常者应行诊断性多期CT或MRI。
  • LI-RADS分级从LR-1(肯定良性)到LR-5(肯定HCC),LR-3为中等恶性概率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Early hepatocellular cancer (HCC) detection is associated with curative treatment and improved survival.1 The American Association for the Study of Liver Diseases recommends semiannual ultrasound and α-fetoprotein (AFP) in patients with cirrhosis, and those with abnormal results should undergo diagnostic multiphase computed tomography (CT) or magnetic resonance imaging (MRI).2 The Liver Imaging Reporting and Data System (LI-RADS) was devised to standardize reporting of liver observations in at-risk individuals, ranging from LR-1 ("definitely benign") to LR-5 ("definitely HCC''), with indeterminate observations classified as LR-3 ("intermediate probability of malignancy").3 A study among 999 cirrhosis patients found that indeterminate liver observations are common, being reported on diagnostic CT or MRI in 98 (38.3%) of 256 patients with abnormal ultrasound results.4 Prior studies have reported a wide range in HCC risk, from 4% to 31%, for LR-3 observations, so there is insufficient evidence to recommend a standardized strategy for monitoring LR-3 observations.5,6.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Arvind A, Joshi S, Zaki T, et al. Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations. Clin Gastroenterol Hepatol. 2021. PMID: 34902571. doi:10.1016/j.cgh.2021.11.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。